Technical Innovations & Patient Support in Radiation Oncology (Jun 2022)
First multicentre experience of SABR for lymph node and liver oligometastatic disease on the unity MR-Linac
- Tomas M. Janssen,
- Katharine Aitken,
- Filippo Alongi,
- Aisling Barry,
- Uffe Bernchou,
- Simon Boeke,
- William A. Hall,
- Ali Hosni,
- Petra.S. Kroon,
- Marcel Nachbar,
- Hina Saeed,
- Ina M. Jürgenliemk-Schulz,
- Tine Schytte,
- Helena M. Verkooijen,
- Marlies.E. Nowee
Affiliations
- Tomas M. Janssen
- Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Corresponding author.
- Katharine Aitken
- Department of Radiotherapy, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, UK
- Filippo Alongi
- Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Negrar, Verona, Italy; University of Brescia
- Aisling Barry
- Radiation Medicine Program, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
- Uffe Bernchou
- Laboratory of Radiation Physics and Department of Oncology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark
- Simon Boeke
- Department for Radiation Oncology, University Hospital Tübingen, Tübingen, Germany
- William A. Hall
- Department of Radiation Oncology, Medical College of Wisconsin, United States
- Ali Hosni
- Radiation Medicine Program, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
- Petra.S. Kroon
- Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
- Marcel Nachbar
- Section for Biomedical Physics, Department of Radiation Oncology, University Hospital Tübingen, Tübingen, Germany
- Hina Saeed
- Department of Radiation Oncology, Medical College of Wisconsin, United States
- Ina M. Jürgenliemk-Schulz
- Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
- Tine Schytte
- Laboratory of Radiation Physics and Department of Oncology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark
- Helena M. Verkooijen
- Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
- Marlies.E. Nowee
- Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
- Journal volume & issue
-
Vol. 22
pp. 50 – 54
Abstract
Summary: The treatment of oligometastatic disease using MR guidance is an evolving field. Since August 2018 patients are treated on a 1.5 Tesla MR-Linac (MRL). We present current workflows and practice standards from seven institutions for the initial patients treated for lymph node and liver metastases.
